Overview

OLP-1002 is Being Studied in the Treatment of Pain.

Status:
Completed

Trial end date:
2020-10-16

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the safety and tolerability of single and multiple subcutaneous doses of OLP-1002 in healthy subjects.

Phase:

Early Phase 1

Details

Lead Sponsor:

OliPass Corporation